GlassScriptPhysician profile
Fernando Aguirre
NPI 1861499444
$2,752.31
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,700 · 2020: $52.07.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $385.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $305.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $264.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $264.01 | 2019 | |
| Astellas Pharma US INC | $192.77 | 2019 | |
| Amgen INC. | $175.11 | 2019 | |
| Lilly USA, LLC | $156.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.33 | 2019 | |
| Abbvie INC. | $104.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $49.84 | 2019 | |
| Gilead Sciences, INC. | $42.40 | 2019 | |
| Mannkind Corporation | $33.16 | 2019 | |
| Amarin Pharma, INC. | $31.34 | 2019 | |
| Coloplast Corp | $27.38 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $13.03 | 2019 | |
| Glaxosmithkline, LLC. | $12.26 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $11.99 | 2019 | |
| Allergan, INC. | $11.79 | 2020 | |
| Boston Scientific Corporation | $11.35 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.24 | 2019 | |
| Janssen Biotech, INC. | $3.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Aguirre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.